Comparative analysis of the pro-inflammatory activity of cellular and humoral immune system components in patients with coronary artery disease with stable angina pectoris and varying degrees of atherosclerotic coronary artery disease
Article Sidebar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Main Article Content
https://orcid.org/0009-0001-3780-3179
Abstract
The aim – to determine the influence of the pro-inflammatory state of cellular and humoral immunity on the severity of coronary atherosclerosis in patients with stable coronary artery disease.
Materials and methods. 115 patients with coronary artery disease (stable angina of exertion in patients of functional class II–IV) were examined. When analyzing coronarograms, the number of affected vessels, the degree and localization of stenoses were taken into account. The total damage to the heart arteries was calculated. The control group consisted of 30 practically healthy individuals with intact coronary arteries. Immunological parameters were studied in peripheral blood taken on an empty stomach.
Results. Multivariate stepwise linear regression analysis revealed a statistically significant complex effect of anti-vascular antibodies (B=0.34; p=0.003), anti-vLDL antibodies (B=0.23; p=0.04) and CIC (B=0.25; p=0.03) on the severity and prevalence of coronary atherosclerosis (F=5.9; p=0.001) with the greatest contribution of anti-vascular antibodies. The use of uncorrelated IL-6, IL-8 (pro-inflammatory cytokines) and MF mts (phagocyte system) in the regression analysis showed a statistically significant effect on the severity and prevalence of atherosclerosis according to SUAS (F=5.9; p=0.001), according to the number of affected CA (F=4.5; p=0.006). The total effect of TNFα (pro-inflammatory cytokine system) and NST NF and MC (phagocyte system) on SUAS (F=3.9; p=0.01) and the number of affected CA (F=3.6; p=0.02) was also revealed. A significant complex effect of uncorrelated inflammatory cytokines (IL-6, TNFα) and humoral immunity (Antibodies to vessels) on the severity and prevalence of coronary atherosclerosis was revealed (F=3.1; p=0.04).
Conclusions. The severity and prevalence of coronary atherosclerosis in stable CHD is associated with the activity of the adaptive cellular, humoral, and innate phagocytic components of the immune system. The severity and prevalence of coronary atherosclerosis in patients with stable CHD is directly affected by the cytokine system – IL-6, IL-8 and IL-10; in the humoral immunity system – Antibodies to arterial wall components, Antibodies to oLDL and CIC. Simultaneous activation of proinflammatory cytokine systems, humoral immunity and phagocytes also have a direct cumulative effect on the severity and prevalence of coronary atherosclerosis.
Article Details
Keywords:
References
Bea АМ, González-Guerrero А, Cenarro А, Lamiquiz-Moneo І, Climent Е, Jarauta Е. Association of HDL cholesterol with all-cause and cardiovascular mortality in primary hypercholesterolemia. Atherosclerosis. 2025;400:118617. https://doi.org/10.1016/j.atherosclerosis.2024.118617
Timmis A, Townsend N, Gale CP, Torbica A, Lettino M et al. European Society of Cardiology: cardiovascular disease statistics 2019. Eur. Heart J. 2020;41:12-85. https://doi.org/10.1093/ehjqcco/qcz065
Kobiyama K, Ley K. Atherosclerosis. Circ Res. 2018;123:1118–1120. https://doi.org/10.1161/CIRCRESAHA.118.313816
Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circulation Res. 2019;124(2):315-327. https://doi.org/10.1161/ CIRCRESAHA.118.313591
Engelen SE, Robinson AJB, Zurke Y-X, Monaco С. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nature Reviews Cardiol. 2022;19(8):522-542. https://doi.org/10.1038/s41569-021-00668-4
Ridker PM. How common is residual inflammatory risk? Circ Res. 2017;120(4):617-619. https://doi.org/10.1161/circresaha.116.310527
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847. https://doi.org/10.1056/nejmoa2021372
Tsiantoulas D, Eslami M, Obermayer G, Clement M, Smeets D, et al. APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans. Nature. 2021;597(7874):92-96. https://doi.org/10.1038/s41586-021-03818-3
Hovland A, Jonasson L, Garred P, et al. The complement system and tolllike receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis. 2015;241(2):480-494. https://doi.org/10.1016/j.atherosclerosis.2015.05.038
Marcovecchio PM, Thomas GD, Mikulski Z, et al. Scavenger receptor CD36 directs nonclassical monocyte patrolling along the endothelium during early atherogenesis. Arterioscler Thromb Vasc Biol. 2017;37:2043-2052. https://doi.org/10.1161/atvbaha.117.309123
Bäck M, Yurdagul AJ, Tabas I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16:389-406. https://doi.org/10.1038/s41569-019-0169-2
Zernecke A. Winkels H, Cochain C, Williams JW, Wolf D, et al. Meta-analysis of leukocyte diversity in atherosclerotic mouse aortas. Circ. Res. 2020;127(3):402-426. https://doi.org/10.1161/circresaha.120
Li Q, Ming T, Wang Y, Ding S, Hu C, Zhang C, et al. Increased Th9 cells and IL-9 levels accelerate disease progression in experimental atherosclerosis. Am J Transl Res. 2017;9:1335-1343. https://doi.org/10.11569/wcjd.v26.i20.1263
Krishnaswamy JK, Alsén S, Yrlid U, Eisenbarth SC. Williams A. Determination of T follicular helper cell fate by dendritic cells. Front Immunol. 2018;9:2169. https://doi.org/10.3389/fimmu.2018.02169
Neupane R, Jin X, Sasaki T, Li X, Murohara T, Cheng XW. Immune Disorder in Atherosclerotic Cardiovascular Disease – Clinical Implications of Using Circulating T-Cell Subsets as Biomarkers. Circulation. 2019;83(7):1431-1438. https://doi.org/10.1253/circj.CJ-19-0114
Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(21):2625-2641. https://doi.org/10.1016/j.jacc.2018.09.042
Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606. https://doi.org/10.1016/s0002-9149(83)80105-2
Tsiantoulas B, Tsiantoulas D, Sage AP, et al. Cells in Atherosclerosis: Closing the Gap From Bench to Bedside. Arteriosc Thromb Vasc Biol. 2015;35(2):296-302. https://doi.org/10.1161/atvbaha.114.303569
Olson NC, Sitlani CM, Doyle MF, Huber SA, Landay AL. Innate and adaptive immune cell subsets as risk factors for coronary heart disease in two population-based cohorts. Atherosclerosis. 2020;300:47-53. https://doi.org/10.1016/j.atherosclerosis.2020.03.011
Fani L, van Dam-Nolen DHK, Vernooij M, Kavousi M. Circulatory markers of immunity and carotid atherosclerotic plaque. Atherosclerosis. 2021;325:69-74. https://doi.org/10.1016/j.atherosclerosis.2021.03.040
Uyemura K, Demer LL, Castle SC. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest. 1996;97:2130-2138. https://doi.org/10.1172/jci118650
De Waal-Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915-924. https://doi.org/10.1084/jem.174.4.915
Hashimoto S, Yamada M, Motoyoshi K, et al. Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10. Blood. 1997;89(1):315-321. https://doi.org/10.1182/blood.v89.1.315
Battes LC, Cheng JM, Oemrawsingh RM, Boersma E, Garcia-Garcia HM, et al. Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: Results from the ATHEROREMO-IVUS study. Atherosclerosis. 2014;236(1):18-24. https://doi.org/10.1016/j.atherosclerosis.2014.06.010
Puz P, Lasek-Bal A. Repeated measurements of serum concentrations of TNF-alpha, interleukin-6 and interleukin-10 in the evaluation of internal carotid artery stenosis progression. Atherosclerosis. 2017;263:97-103. https://doi.org/10.1016/j.atherosclerosis.2017.06.008
Malarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart. 2008;94:724-729. https://doi.org/10.1136/hrt.2007.119271
Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res. 2014;114:1743-1756. https://doi.org/10.1161/circresaha.113.301145
Steinberg D, Witztum JL. Oxidized Low-Density Lipoprotein and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30:2311-2316. https://doi.org/10.1161/atvbaha.108.179697
Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008;200(2):239-246. https://doi.org/10.1016/j.atherosclerosis.2008.03.025
Fang JC, Kinlay S, Behrendt D, et al. Circulating antibodies to oxidized LDL correlate with impaired coronary endothelial fuinction after cardiac trans plantation. Arterioscler Thromb Vase Biol. 2002;22:2044-2050. https://doi.org/10.1161/01.atv.0000040854.47020.44
Ghattas A, Griffiths HR, Devitt A, et al. Monocytes in Coronary Artery Disease and Atherosclerosis: Where Are We Now? J Am Coll Cardiol. 2013;62(17):1541-1551. https://doi.org/10.1016/j.jacc.2013.07.043
Yamamoto E, Sugiyama S, Hirata Y, et al. Prognostic significance of circulating leukocyte subtype counts in patients with coronary artery disease. Atherosclerosis. 2016;255:210-216. https://doi.org/10.1016/j.atherosclerosis.2016.08.033
Gijsberts CM, Ellenbroek GHJM, ten Berg MJ, et al. Effect of Monocyte-to-Lymphocyte Ratio on Heart Failure Characteristics and Hospitalizations in a Coronary Angiography Cohort. Amer J Cardiol. 2017;120(6):911-916. https://doi.org/10.1016/j.amjcard.2017.06.020
Anoop DS, Denaxas S, Nicholas O, Hingorani AD, Hemingway H. Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases. A CALIBER Cohort Study. J Amer Coll Cardiol. 2017;69(9):114-123. https://doi.org/10.1016/j.jacc.2016.12.022
Ensan S, Li A, Besla R, et al. Self-renewing resident arterial macrophages arise from embryonic CX3CR1(+) precursors and circulating monocytes immediately after birth. Nat Immunol. 2016;17:159-168. https://doi.org/10.1038/ni.3343.
Mallat Z. Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;37:e92-e98. https://doi.org/10.1161/atvbaha.117.309730
Barrett TJ. Macrophages in Atherosclerosis Regression. Arteriosclerosis, Thrombosis, and Vascular Biology. 2020;40(1):20-33. https://doi.org/10.1161/atvbaha.119.312802
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-325. https://doi.org/10.1038/nature10146
Battes LC, Cheng JM, Oemrawsingh RM, et al. Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: Results from the ATHEROREMO-IVUS study. Atherosclerosis. 2014;236(1):18-24. https://doi.org/10.1016/j.atherosclerosis.2014.06.010
Edsfeldt A, Grufman H, Asciutto G, et al. Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis. 2015;241(2):443-449. https://doi.org/10.1016/j.atherosclerosis.2015.05.019